@article {27040,
	title = {tRNA-Derived Fragments (tRFs) in Bladder Cancer: Increased 5{\textquoteright}-tRF-LysCTT Results in Disease Early Progression and Patients{\textquoteright} Poor Treatment Outcome},
	journal = {Cancers (Basel)},
	volume = {12},
	number = {12},
	year = {2020},
	note = {Papadimitriou, Maria-AlexandraAvgeris, MargaritisLevis, PanagiotisPapasotiriou, Evangelia ChKotronopoulos, GeorgiosStravodimos, KonstantinosScorilas, AndreasengT2EDK-02196/This research has been co-financed by the European Regional Development Fund of the European Union and Greek national funds through the Operational Program Competitiveness, Entrepreneurship and Innovation, under the call RESEARCH - CREATE - INNOVATE (projSwitzerland2020/12/10 06:00Cancers (Basel). 2020 Dec 6;12(12). pii: cancers12123661. doi: 10.3390/cancers12123661.},
	month = {Dec 6},
	abstract = {The heterogeneity of bladder cancer (BlCa) prognosis and treatment outcome requires the elucidation of tumors{\textquoteright} molecular background towards personalized patients{\textquoteright} management. tRNA-derived fragments (tRFs), although originally considered as degradation debris, represent a novel class of powerful regulatory non-coding RNAs. In silico analysis of the TCGA-BLCA project highlighted 5{\textquoteright}-tRF-LysCTT to be significantly deregulated in bladder tumors, and 5{\textquoteright}-tRF-LysCTT levels were further quantified in our screening cohort of 230 BlCa patients. Recurrence and progression for non-muscle invasive (NMIBC) patients, as well as progression and patient{\textquoteright}s death for muscle-invasive (MIBC) patients, were used as clinical endpoint events. TCGA-BLCA were used as validation cohort. Bootstrap analysis was performed for internal validation and the clinical net benefit of 5{\textquoteright}-tRF-LysCTT on disease prognosis was assessed by decision curve analysis. Elevated 5{\textquoteright}-tRF-LysCTT was associated with unfavorable disease features, and significant higher risk for early progression (multivariate Cox: HR = 2.368; p = 0.033) and poor survival (multivariate Cox: HR = 2.151; p = 0.032) of NMIBC and MIBC patients, respectively. Multivariate models integrating 5{\textquoteright}-tRF-LysCTT with disease established markers resulted in superior risk-stratification specificity and positive prediction of patients{\textquoteright} progression. In conclusion, increased 5{\textquoteright}-tRF-LysCTT levels were strongly associated with adverse disease outcome and improved BlCa patients{\textquoteright} prognostication.},
	keywords = {5{\textquoteright}-tRFs, Bladder cancer, bladder tumors, bladder urothelial carcinoma, ncRNAs, non coding RNAs, tRNA fragments, tRNA-derived fragments, tRNA-Lys-CTT, tRNALysCTT},
	isbn = {2072-6694 (Print)2072-6694 (Linking)},
	author = {Papadimitriou, M. A. and Avgeris, M. and Levis, P. and Papasotiriou, E. C. and Kotronopoulos, G. and Stravodimos, K. and Scorilas, A.}
}
